AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL
· Real-Time Price · USD
2.31
0.17 (7.94%)
At close: Jun 03, 2025, 3:59 PM
2.38
2.81%
Pre-market: Jun 04, 2025, 07:35 AM EDT
Company Description
AbCellera Biologics Inc. develops antibody discovery platform.
Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs.
As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.

Country | CA |
IPO Date | Dec 11, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 596 |
CEO | Dr. Carl L.G. Hansen Ph.D. |
Contact Details
Address: 2215 Yukon Street Vancouver, BC CA | |
Website | https://www.abcellera.com |
Stock Details
Ticker Symbol | ABCL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001703057 |
CUSIP Number | 00288U106 |
ISIN Number | CA00288U1066 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President & Chairperson |
Andrew Booth M.B.A. | Chief Financial Officer |
Dr. Veronique Lecault Ph.D. | Chief Technology Officer & Director |
Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer |
Adam Clarke M.A.I.C.D., Ph.D. | Senior Vice President of Discovery |
Graham Craig M.Sc. | Director of Corporate Development |
Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting |
Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 30, 2025 | 8-K | Current Report |
May 14, 2025 | 8-K | Current Report |
May 13, 2025 | 8-K | Current Report |
May 08, 2025 | 10-Q | Quarterly Report |
May 08, 2025 | 8-K | Current Report |
Apr 29, 2025 | ARS | Filing |
Apr 29, 2025 | DEFA14A | Filing |
Apr 29, 2025 | DEF 14A | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 10, 2025 | 4 | Filing |